C Carl Jaffe

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Measures of response: RECIST, WHO, and new alternatives
    C Carl Jaffe
    Diagnostic Imaging Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 24:3245-51. 2006
  2. ncbi Response assessment in clinical trials: implications for sarcoma clinical trial design
    C Carl Jaffe
    National Cancer Institute, 6116 Executive Boulevard, Bethesda, Maryland 20892, USA
    Oncologist 13:14-8. 2008
  3. ncbi Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Lori E Dodd
    Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 26:3791-6. 2008

Detail Information

Publications3

  1. ncbi Measures of response: RECIST, WHO, and new alternatives
    C Carl Jaffe
    Diagnostic Imaging Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 24:3245-51. 2006
    ....
  2. ncbi Response assessment in clinical trials: implications for sarcoma clinical trial design
    C Carl Jaffe
    National Cancer Institute, 6116 Executive Boulevard, Bethesda, Maryland 20892, USA
    Oncologist 13:14-8. 2008
    ..Reviewing existing and new approaches in the design of clinical trials will help to optimize the clinical development and evaluation of new therapies for sarcomas...
  3. ncbi Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Lori E Dodd
    Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 26:3791-6. 2008
    ..When such designs are not practical, BICR is not recommended as a general strategy for reducing bias. However, BICR may be useful as an auditing tool to assess the reliability of marginally positive results...